US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer. The KEYLYNK-001 study evaluated a treatment regimen ...
Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...
Merck (MRK) announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA plus chemotherapy followed by maintenance with LYNPARZA, with or without bevacizumab, as a first-line treatment for ...
RAHWAY, N.J., December 09, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ...
The phase 3 KEYLYNK-001 study, which evaluates Keytruda plus chemotherapy, followed by Lynparza maintenance, with or without Avastin, has met its primary endpoint, staving off progression of the ...
On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (pembrolizumab) plus chemotherapy followed by ...
RAHWAY, N.J., December 09, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback